Disease · MONDO_0005264
Comparisons in its trials26
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 26
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
Secondary Prevention Cohort (Balanced): Apixaban vs Secondary Prevention Cohort (Balanced): Warfarin: Number of Participants With Risk of a Composite of Recurrent Stroke or SE at 18 Months: Secondary Prevention (Balanced) Cohorts | 1,095 of 7,796 | 1,272 of 11,601 | 19,397 | NCT05321810 | Trial comparisons |
Secondary Prevention Cohort (Balanced): Apixaban vs Secondary Prevention Cohort (Balanced): Warfarin: Number of Participants With Risk of a Composite of Recurrent Stroke or SE at 6 Months: Secondary Prevention (Balanced) Cohorts | 2,061 of 7,796 | 2,393 of 11,601 | 19,397 | NCT05321810 | Trial comparisons |
Secondary Prevention Cohort (Balanced): Apixaban vs Secondary Prevention Cohort (Balanced): Warfarin: Number of Participants With Risk of a Composite of Recurrent Stroke or SE at 0 Month: Secondary Prevention (Balanced) Cohorts | 7,796 of 7,796 | 11,601 of 11,601 | 19,397 | NCT05321810 | Trial comparisons |
Secondary Prevention Cohort (Balanced): Apixaban vs Secondary Prevention Cohort (Balanced): Warfarin: Number of Participants With Risk of Major Bleeding at 18 Months: Secondary Prevention (Balanced) Cohorts | 1,110 of 7,796 | 1,283 of 11,601 | 19,397 | NCT05321810 | Trial comparisons |
Secondary Prevention Cohort (Balanced): Apixaban vs Secondary Prevention Cohort (Balanced): Warfarin: Number of Participants With Risk of Major Bleeding at 24 Months: Secondary Prevention (Balanced) Cohorts | 850 of 7,796 | 1,028 of 11,601 | 19,397 | NCT05321810 | Trial comparisons |
Secondary Prevention Cohort (Balanced): Apixaban vs Secondary Prevention Cohort (Balanced): Warfarin: Number of Participants With Risk of Major Bleeding at 0 Month: Secondary Prevention (Balanced) Cohorts | 7,796 of 7,796 | 11,601 of 11,601 | 19,397 | NCT05321810 | Trial comparisons |
Secondary Prevention Cohort (Balanced): Apixaban vs Secondary Prevention Cohort (Balanced): Warfarin: Number of Participants With Risk of a Composite of Recurrent Stroke or SE at 24 Months: Secondary Prevention (Balanced) Cohorts | 845 of 7,796 | 1,024 of 11,601 | 19,397 | NCT05321810 | Trial comparisons |
Secondary Prevention Cohort (Balanced): Apixaban vs Secondary Prevention Cohort (Balanced): Warfarin: Number of Participants With Risk of a Composite of Recurrent Stroke or SE at 12 Months: Secondary Prevention (Balanced) Cohorts | 1,426 of 7,796 | 1,670 of 11,601 | 19,397 | NCT05321810 | Trial comparisons |
Secondary Prevention Cohort (Balanced): Apixaban vs Secondary Prevention Cohort (Balanced): Warfarin: Number of Participants With Risk of Major Bleeding at 12 Months: Secondary Prevention (Balanced) Cohorts | 1,448 of 7,796 | 1,685 of 11,601 | 19,397 | NCT05321810 | Trial comparisons |
Secondary Prevention Cohort (Balanced): Apixaban vs Secondary Prevention Cohort (Balanced): Warfarin: Number of Participants With Risk of Major Bleeding at 6 Months: Secondary Prevention (Balanced) Cohorts | 2,081 of 7,796 | 2,412 of 11,601 | 19,397 | NCT05321810 | Trial comparisons |
| Tenecteplase (tNK) vs Control (Antiplatelet Agents): Number of Participants With Return to Baseline Neurological Functioning Measured by the Modified Rankin Scale (mRS) | 309 of 432 | 338 of 452 | 884 | NCT02398656 | Trial comparisons |
| Tenecteplase (tNK) vs Control (Antiplatelet Agents): Number of Participants With Modified Rankin Score (mRS) 0-1 at 90 Days | 298 of 432 | 321 of 452 | 884 | NCT02398656 | Trial comparisons |
| Tenecteplase (tNK) vs Control (Antiplatelet Agents): serious adverse events | 16 of 432 | 2 of 452 | 884 | NCT02398656 | Trial comparisons |
| Tenecteplase (tNK) vs Control (Antiplatelet Agents): deaths from any cause | 20 of 425 | 5 of 442 | 867 | NCT02398656 | Trial comparisons |
| Stent Group vs Medical Therapy Group: serious adverse events | 30 of 58 | 20 of 53 | 111 | NCT00816166 | Trial comparisons |
| Dabigatran 110 mg BID vs Dabigatran 150mg BID: Any Parenchymal Haemorrhage (PH1 or PH2) | 3 of 37 | 3 of 64 | 101 | NCT02415855 | Trial comparisons |
| Dabigatran 110 mg BID vs Dabigatran 150mg BID: Symptomatic Hemorrhagic Transformation Rate (PH2) | 0 of 37 | 0 of 64 | 101 | NCT02415855 | Trial comparisons |
| Dabigatran 110 mg BID vs Dabigatran 150mg BID: Symptomatic Hemorrhagic Transformation Rate | 0 of 37 | 0 of 64 | 101 | NCT02415855 | Trial comparisons |
| Dabigatran 110 mg BID vs Dabigatran 150mg BID: Systemic Hemorrhagic Complication Rate | 0 of 37 | 0 of 64 | 101 | NCT02415855 | Trial comparisons |
| Dabigatran 110 mg BID vs Dabigatran 150mg BID: deaths from any cause | 1 of 37 | 0 of 64 | 101 | NCT02415855 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0005264/comparisons